Skip to content
Next results · Q4 2026Projected

Mar 2, before the open

Tue, Mar 2, 2027in 105 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 25 – Mar 12

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$838.00K
Revenue, change from a year earlier: Q3 2026 +243.9%, Q4 2025 −61.6%, Q3 2025 +486.1%, Q2 2025 n/m
Net income
-$46.08M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Results day

Typical moveA typical move of 7.8% either way

Up after 4 of 12, down after 8.

The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: +10.4% after Q3 2026.

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

When it reports

Usual day
Varies
Session
before the open
After quarter end
37 to 59 days
10-Q filed
37 to 43 days
over its last 8
10-K filed
59 to 68 days
over its last 4

Based on 4 prior 10-K filings.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR